The immunohistochemical analysis of the expression of nuclear protein Ki67, a highly valid proliferation marker, revealed a boundary-significant dose-dependent decline in rat tumor samples of both treated groups by 20.5% and 21.5% vs. control tumors. Here, MKI67 is linked to neoplasm.